Patents by Inventor Paolo Alberto Veronesi

Paolo Alberto Veronesi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11684623
    Abstract: The invention relates to soluble melatonin tripartate adduct comprising three structurally distinct regions and optionally trehalose, its stable sterile lyophilized powder and preservative-free aqueous solution or ointment, and to related pharmaceutical forms thereof, wherein the active melatonin moiety is adducted to a nucleoside in an optimal ratio range, with or without the presence of C2-C5 short chain amino acid. The invention further relates to the pharmaceutical field, more precisely it refers to the ophthalmic use of said melatonin tripartate adduct and to the method to prevent or treat serious ophthalmic pathologies in mammals and humans, more precisely rare and severe eye sight-threatening conditions and neuro-ophthalmic disorders in human and veterinary medicine, wherein said acute and chronic pathophysiological alterations and oculopathies are mainly caused by oxidative stress and related hypoxia-inducible factors (HIFs) and inflammation affecting the eyes.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: June 27, 2023
    Assignee: WORPHMED SRL
    Inventors: Emanuela Peschechera, Paolo Alberto Veronesi
  • Publication number: 20230061569
    Abstract: The invention relates to soluble melatonin tripartate adduct comprising three structurally distinct regions and optionally trehalose, its stable sterile lyophilized powder and preservative-free aqueous solution or ointment, and to related pharmaceutical forms thereof, wherein the active melatonin moiety is adducted to a nucleoside in an optimal ratio range, with or without the presence of C2-C5 short chain amino acid. The invention further relates to the pharmaceutical field, more precisely it refers to the ophthalmic use of said melatonin tripartate adduct and to the method to prevent or treat serious ophthalmic pathologies in mammals and humans, more precisely rare and severe eye sight-threatening conditions and neuro-ophthalmic disorders in human and veterinary medicine, wherein said acute and chronic pathophysiological alterations and oculopathies are mainly caused by oxidative stress and related hypoxia-inducible factors (HIFs) and inflammation affecting the eyes.
    Type: Application
    Filed: December 17, 2020
    Publication date: March 2, 2023
    Inventors: Emanuela PESCHECHERA, Paolo Alberto VERONESI
  • Patent number: 10342779
    Abstract: The present invention relates to a concentrated melatonin solution, wherein melatonin is present in a quantity of 10.0% or higher in a substantially water-free carrier mixture of ethanol and a polyethoxylated derivative. The concentrated solution, free of preserving agents, is suitable to prepare injectable sterile compositions for parenteral administration, or formulations for topical or oral administration. The invention also encompasses a method for the preparation of the concentrated solution, as well as the possible benefits of the intravenous infusion of high levels of melatonin as adjuvant therapy in Ebola or Dengue hemorrhagic fever (DHF) or as an anti-oxidant/anti-aging treatment.
    Type: Grant
    Filed: October 12, 2015
    Date of Patent: July 9, 2019
    Assignee: WORPHMED SRL
    Inventors: Paolo Alberto Veronesi, Emanuela Peschechera, Susanna Veronesi
  • Publication number: 20170239217
    Abstract: The present invention relates to a concentrated melatonin solution, wherein melatonin is present in a quantity of 10.0% or higher in a substantially water-free carrier mixture of ethanol and a polyethoxylated derivative. The concentrated solution, free of preserving agents, is suitable to prepare injectable sterile compositions for parenteral administration, or formulations for topical or oral administration. The invention also encompasses a method for the preparation of the concentrated solution, as well as the possible benefits of the intravenous infusion of high levels of melatonin as adjuvant therapy in Ebola or Dengue hemorrhagic fever (DHF) or as an anti-oxidant/anti-aging treatment.
    Type: Application
    Filed: October 12, 2015
    Publication date: August 24, 2017
    Inventors: Paolo Alberto VERONESI, Emanuela PESCHECHERA, Susanna VERONESI
  • Patent number: 9284292
    Abstract: The present invention discloses a new class of compounds that exhibit an inhibitory effect on influenza virus type A and B, which may or may not be resistant to other drugs, as well as on other types of viruses, such as flavivirus but also on protozoa and other micro-organisms, their preparation methods, pharmaceutical formulations containing them and their use as medicinal products for the treatment of various conditions caused by particular microorganisms, including viruses, bacteria and protozoa, which affect animal and human health.
    Type: Grant
    Filed: November 25, 2010
    Date of Patent: March 15, 2016
    Assignee: THERAPICON S.R.L.
    Inventors: Paolo Alberto Veronesi, Pablo E. A. Rodriguez, Anna Maria Veronesi, Emanuela Peschechera
  • Publication number: 20120269771
    Abstract: The present invention discloses a new class of compounds that exhibit an inhibitory effect on influenza virus type A and B, which may or may not be resistant to other drugs, as well as on other types of viruses, such as flavivirus but also on protozoa and other micro-organisms, their preparation methods, pharmaceutical formulations containing them and their use as medicinal products for the treatment of various conditions caused by particular microorganisms, including viruses, bacteria and protozoa, which affect animal and human health.
    Type: Application
    Filed: November 25, 2010
    Publication date: October 25, 2012
    Inventors: Paolo Alberto Veronesi, Pablo E.A. Rodriguez, Anna Maria Veronesi, Emanuela Peschechera
  • Patent number: 8227425
    Abstract: The invention provides a new class of compounds exhibiting an inhibitory effect on neuraminidase (NA), hemagglutinin (HA) and structural M2 protein bearing viruses. These compounds are also useful as inhibitors of the replication factors of hepatitis virus type C (HVC). The invention also describes pharmaceutical compositions containing the compounds of the invention either alone or in combination admixed with a suitable and pharmaceutically acceptable carrier.
    Type: Grant
    Filed: January 22, 2008
    Date of Patent: July 24, 2012
    Assignee: Therapicon Srl
    Inventors: Paolo Alberto Veronesi, Pablo Eduardo Andres Rodriguez, Emanuela Peschechera, Susanna Lucia Veronesi
  • Publication number: 20100029579
    Abstract: The invention provides a new class of compounds exhibiting an inhibitory effect on neuraminidase (NA), hemagglutinin (HA) and structural M2 protein bearing viruses. These compounds are also useful as inhibitors of the replication factors of hepatitis virus type C (HVC). The invention also describes pharmaceutical compositions containing the compounds of the invention either alone or in combination admixed with a suitable and pharmaceutically acceptable carrier.
    Type: Application
    Filed: January 22, 2008
    Publication date: February 4, 2010
    Applicant: Therapicon Srl
    Inventors: Paolo Alberto Veronesi, Pablo Eduardo Andres Rodriguez, Emanuela Peschechera, Susanna Lucia Veronesi
  • Publication number: 20090035260
    Abstract: A pharmaceutical composition has a therapeutically effective amount of at least one of: a pharmaceutically active nasal peptide, its pharmaceutically acceptable salt and its peptidic fragment. The composition also contains an absorbefacient effective amount of THAM in a pharmaceutically acceptable, aqueous liquid diluent or carrier. The composition is provided in a convenient form for nasal administration. In one embodiment, the peptidic fragment may be selected physiologically active lymphokines and monokines, peptidic enzymes, proteic vaccines, peptidic toxoids and personalized proteins derived from genoma. In another embodiment, the peptidic fragment may be selected from the peptide hormones and hormone antagonists buserelin, desmopressin, vasopressin, angiotensin, felypressin, octreotide, somatropin, thyrotropin (TSH), somatostatin, gosereline, thryptorelin and insulin selected from the group consisting of cow and pig, synthetic and recombinant.
    Type: Application
    Filed: August 5, 2008
    Publication date: February 5, 2009
    Applicant: THERAPICON SRL
    Inventors: Paolo Alberto Veronesi, Pablo E.A. Rodriguez
  • Publication number: 20080286257
    Abstract: The invention relates to the modification of recombinant human lysozyme from genetic engineering (rHLys) by reacting with activated polyethylene glycols (PEGs), which are partially binding or saturating with typical linkers one or more out of the six free amino groups of the five lysines (K) present in the rHLys chain. The resulting conjugate compounds of the invention (PEG-rHLys) and their addition salts, inhibit the abnormal cell proliferation and show remarkable antiproliferative and antimetastatic effects. The invention relates also to the use of the new compounds in the preparation of pharmaceutical compositions for treating a disease associated with abnormal cell proliferation, including cancer, by administering said conjugates to a subject in need thereof.
    Type: Application
    Filed: September 29, 2006
    Publication date: November 20, 2008
    Applicant: THERAPICON Srl
    Inventors: Paolo Alberto Veronesi, Pablo E.A. Rodriguez
  • Publication number: 20080153915
    Abstract: A throat, mouth and/or gum sprayable pharmaceutical preparation in the form of an aqueous solution. One embodiment of such a solution may comprise: a non-steroidal anti-inflammatory drug (NSAID) also having analgesic activity; a biologically compatible buffer consisting essentially of an organic amine selected from at least one D-glucamine, meglumine, trometamol (tris buffer) and a mixture thereof, in a quantity suitable for buffering the pH of the preparation within the range of between about 6.5 and about 8.0; and pharmaceutical grade water; wherein the NSAID is flurbiprofen.
    Type: Application
    Filed: December 20, 2004
    Publication date: June 26, 2008
    Applicant: THERAPICON S.R.L.
    Inventor: Paolo Alberto Veronesi
  • Patent number: 7012062
    Abstract: Use of modified lysozyme c or its pharmaceutically acceptable salts and its industrial production for the preparation of medicinal compositions, suitable for oral, parenteral and topical administration, for prophylaxis and therapy of diseases in mammals.
    Type: Grant
    Filed: August 26, 2002
    Date of Patent: March 14, 2006
    Assignee: Therapicon SRL
    Inventors: Paolo Alberto Veronesi, Paolo E. A. Rodriguez
  • Patent number: 6855835
    Abstract: Allomorph of Z isomer of N-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N?-methyl-2-nitro-1,1-ethenediamine hydrochloride, with two carbon atoms linked by a rigid ethylenic bond, marked by an asterisk (*), characterized by the following structural formula: wherein -Fur- represents a furane ring.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: February 15, 2005
    Assignee: Pharmexcel SRL
    Inventor: Paolo Alberto Veronesi
  • Publication number: 20040048922
    Abstract: Allomorph of Z isomer of N-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N′-methyl-2-nitro-1,1-ethenediamine hydrochloride, with two carbon atoms linked by a rigid ethylenic bond, marked by an asterisk (*), characterized by the following structural formula: 1
    Type: Application
    Filed: August 29, 2002
    Publication date: March 11, 2004
    Inventor: Paolo Alberto Veronesi
  • Patent number: 6251429
    Abstract: Programmed-release ambroxol·HCl pharmaceutical dosage forms, adopted to maintain a therapeutically effective plasma level thereof for about 24 hours, comprise a plurality of inert core microgranules of a variety of particle sizes ranging from 0.3 to 1.2 mm, such inert core microgranules being coated with alternating microlayers of (1) micronized ambroxol hydrochloride active agent and (2) delayed-release film material, such coated microgranules including an external microlayer of delayed-release film material, and such coated mi.crogranules having particle sizes ranging from 0.6 to 1.5 mm.
    Type: Grant
    Filed: January 30, 1995
    Date of Patent: June 26, 2001
    Assignee: Therapicon slr
    Inventors: Paolo Alberto Veronesi, Anna Maria Veronesi
  • Patent number: 6107277
    Abstract: Salcatonin (i.e. salmon calcitonin) analogues of formula R1-Ser-Asn-Leu-Ser-Thr-Cys(SR2)-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Ly s-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro-NH2 (I) are disclosed, in which R1=-Cys-S--H, -Cys--OH, -Cys-S-ether or -Cys-S-ester (where the ether or ester residue has 2-5C) or a corresponding salt or isomer; R2=H, OH, ester or ether residue of 2-5C or acetamidomethyl, or a corresponding salt or isomer.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: August 22, 2000
    Assignee: Therapicon S.R.L.
    Inventors: Paolo Alberto Veronesi, Emanuela Peschechera, Anna Maria Veronesi
  • Patent number: 6087338
    Abstract: The subject-matter of the invention are pharmaceutical non inorganic saline solutions for endonasal administration containing: (a) a calcitonin, preferably salmon or alternatively carbacalcitonin (elcatonin), or its pharmaceutically acceptable salts; characterized in that it further contains the organic excipients; (b) N-(methyl)-glucamine or glucamine; (c) tromethamine; (d) citric acid; and (e) polyvinylpyrrolidone ranging from K15 to K120. These are odorless and tasteless and thus have improved patient's compliance not having the undesirable secondary effects of known compositions as well as permit a complete and accurate analysis of the active principle and develop less degradation products during storage.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: July 11, 2000
    Assignee: Therapicon S.R.L.
    Inventors: Paolo Alberto Veronesi, Emanuela Peschechera, Anna Maria Veronesi
  • Patent number: 5814338
    Abstract: The present invention deals with a pharmaceutical product in unit dosage form and a unit dosage drug delivery system which comprises a multiple layer capsule or housing having two or more layers, the layers being of materials, wherein the outer layer possesses a hydrophilic character and the inner layer possesses a hydrophobic character, and a capsule filling wherein one or more drug substances are admixed, dissolved, suspended or agglomerated in a hydrophobic support.
    Type: Grant
    Filed: January 9, 1997
    Date of Patent: September 29, 1998
    Assignee: Therapicon S.R.L.
    Inventor: Paolo Alberto Veronesi